Overview

A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer

Status:
Terminated

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

This is an open multicenter randomized phase I/II study. The main purpose with this study is to investigate dose and efficacy of a combination of Irinotecan, Cetuximab and Everolimus given biweekly to patients with local advanced or metastatic pancreatic cancer AFTER progression from 1. line treatment with Gemcitabine.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Per Pfeiffer

Collaborators:

Aarhus University Hospital
Odense University Hospital

Treatments:

Camptothecin
Capecitabine
Cetuximab
Everolimus
Irinotecan
Oxaliplatin
Sirolimus